Abstract:In England, and many other countries, immunity to SARS-CoV-2 infection and COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary and booster vaccination, while protection has been lost through waning immunity and viral mutation. During the height of the pandemic in England, the main aim was to rapidly protect the population and large supplies of vaccine were pre-purchased, eliminating the need for cost-effective calculations. As we move to an era where for the majority of the population SARS-CoV-2 infections cause relatively mild disease, and vaccine stocks need to be re-purchased, it is important we consider the cost-effectiveness and economic value of COVID-19 vaccination programmes. Here using data from 2023 and 2024 in England on COVID-19 hospital admissions, ICU admissions and deaths, coupled with bespoke health economic costs, we consider the willingness to pay threshold for COVID-19 vaccines in different age and risk groups. We partition the population into sixteen 5-year age-groups and three risk groups (no-risk, at-risk and immunosuppressed) and calculate the health savings, in terms of costs and quality adjusted life years (QALYs), per vaccine dose. We adopt three different methodological approaches to estimate the level of vaccine protection leading to five different estimates of efficacy. Willingness to pay thresholds vary from less than 1 GBP for younger age-groups without any risk factors, to over 100 GBP for older age-groups with comorbidities that place them at risk. This extreme non-linear dependence on age, means that despite the different method of estimating vaccine efficacy, there is considerable qualitative agreement on the willingness to pay threshold, and therefore which ages it is cost-effective to vaccinate. For pre-purchased vaccine, where the only cost is administration (≈10 GBP), a twice-yearly universal booster offer to all those aged 70 and over is cost-effective (the benefits outweigh the administration costs), while for the at-risk group this could be extended to those over 65. When the vaccine cost is included, the cost-effective ages reduce, such that at a total cost of 30GBP (for vaccine and administration) universal vaccine is only cost-effective for those over 75; while at 60GBP universal vaccine is only cost-effective for those over 80. The historic offer of COVID-19 vaccination to those 65 and over for the autumn 2023 programme and those over 75 for the spring 2023 programme, aligns with our cost-effective threshold for pre-purchased vaccine when the only cost was administration. However, for future programmes, when vaccine costs are included, the age-thresholds slowly increase thereby demonstrating the continued importance of protecting the eldest and most vulnerable in the population.

Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan

Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly

Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial

The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan

Cost-effectiveness Analysis of BNT162b2 COVID-19 Booster Vaccination in the United States

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine

Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China

Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan

The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study

Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany

Cost-effectiveness of routine COVID-19 adult vaccination programmes in England

One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial

Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case-Control Study

A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine

An Age-Specific Crisis Awareness Survey of COVID-19 Vaccines and Treatments Among Healthy Japanese Adults